ClinicalTrials.gg
RecruitingNCT07516184SOLAUpdated Oct 13, 2026

Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis

An interventional study of Pulmonary function Test intervention in Suspected Asthma, sponsored by AstraZeneca. Recruiting at 24 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AstraZeneca · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 13, 2026Site recruiting status changed1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Planned enrollment
72nd of 248
500 · median 175
Started
2026
with 9 others
No phase
6 of 359
2 open now
Primary completion
2027-06
later than 7 of 27 live
Registered
353rd of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 72nd largest by planned enrollment of the 248 interventional ones that give a count, is one of 10 that started in 2026, is one of 6 with no phase, reaches primary completion later than 7 of the 27 other live ones, and was the 353rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

This is a multi-center study to explore the positive predictive value of bronchodilation test with portable oscillometry compared to either BDT or BPT with spirometry in asthma diagnosis and to compare it with bronchodilation with spirometry (the current gold standard). In the study, the target patients' profile is the suspected asthma patient with asthmatic symptoms (wheezing, shortness of breath, chest tightness, and/or cough) and aim to enroll 500 participants from 25 sites across different regions in China.

Read the detailed description

Following the completion of informed consent procedures, patients with asthmatic symptoms will proceed to enrollment for inclusion and exclusion criteria review. In addition, blood tests, include complete blood count (CBC) and C-reactive protein (CRP), and chest Computed Tomography (CT) will be done for eligible participants prior to all assessments in the study to ensure excluding participants with respiratory infections and any lung diseases (other than asthma).

All the included participants will undergo Fractional exhaled nitric oxide (FeNO) test, BDT with portable oscillometry and spirometry in sequence and complete the Asthma Control Questionnaire-5 (ACQ-5) assessment during Visit 1. For participants with pre-BD FEV1% ≥ 70% will undergo BPT with spirometry as the last assessment in the study.

The diagnosis of asthma will be defined as positive BDT (after bronchodilator inhalation, FEV1 increased by ≥12%, and the absolute value of FEV1 increased by ≥200 mL) or positive BPT with spirometry (FEV1% decrease ≥20% after methacholine inhalation). Oscillometry BDT positive is defined as R5 decrease 40%, or X5 increase 50%, or AX decrease 80% after bronchodilator inhalation as recommended in ERS consensus.

03

Conditions studied

  • Suspected Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all the following criteria and sign an form (ICF) to be eligible for the study.

  1. Patient must be aged 18-75 years old at the time of enrollment.
  2. Presented with asthmatic symptoms such as wheezing, shortness of breath, chest tightness and cough ≥2 months prior to enrollment (Day 0), with/without an established asthma diagnosis.

Exclusion criteria

Exclusion Criteria:

Patients are excluded from the study if any of the following criteria apply:

Medical Conditions

  1. Respiratory infections within 3 months prior to enrollment (Day 0), including but not limited to: acute bacterial/viral pneumonia, acute bronchitis, Influenza, COVID-19 or acute exacerbation of chronic bronchitis.
  2. Current smoker; or cessation from smoking less than 6 months; or cessation smoking for more than 6 months but smoked more than 10 packs/year.
  3. History of other chronic respiratory diseases other than asthma, including but not limited to tuberculosis, significant bronchiectasis, established interstitial lung disease, and lung cancer.
  4. History of serious comorbidities, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:

    1. Affect the safety of the patient throughout the study,
    2. Confound the study results or impact the scientific validity of the data outcome,
    3. Impede the patient's ability to complete the entire duration of study.
  5. Positive urine pregnancy test, or breastfeeding women, or any women who are planning to become pregnant (current and within 3 months).

    Prior/Concomitant Therapy

  6. ICS-based medication (including ICS, ICS/LABA, ICS/LABA/LAMA) use within 3 months prior to enrollment (Day 0).

    ICS=inhaled ; LABA=long-acting β2 agonists; LAMA=long-acting muscarinic antagonists.

    Other Exclusions

  7. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  8. Current participation in another interventional clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Other
    Pulmonary function Test intervention

    enrollment 500 suspect asthma patients

    Device: Pulmonary function Test intervention

Interventions

  • DevicePulmonary function Test intervention

    enrollment 500 suspect asthma patients

06

What researchers measure

Primary outcomes

  1. To explore the diagnostic value of portable oscillometry in suspected asthma patients

    PPV (Positive predictive value)(spiro diagnosed asthma/osci BDT ve+) of BDT(Bronchodilation test) with portable oscillomtery in asthma diagnosis

    Time frame: day 0~7

Secondary outcomes

  1. To evaluate the consistency of portable oscillometry BD test with spirometry BDT/BPT in suspected asthma patients

    Kappa coefficient between oscillometry BDT and spirometry BDT/BPT and NPV (non-asthma diagnosed by spiro/osci BDT ve-) of BDT with portable oscillometry in asthma diagnosis

    Time frame: day 0~7

  2. To evaluate the diagnostic performance of portable oscillometry in suspected asthma patients

    Sensitivity (osci BDT ve+/spiro diagnosed asthma) and specificity (osci BDT ve-/non-asthma diagnosed by spiro) of BDT with portable oscillometry in asthma diagnosis. The proportion of osci BDT ve+ who have spiro BPT positive.

    Time frame: day 0~7

  3. To evaluate the diagnostic performance of spirometry in suspected asthma patients

    Sensitivity (spiro BDT ve+/spiro diagnosed asthma) of BDT with spirometry in asthma diagnosis. The proportion of spiro BDT ve+ who have spiro BPT positive.

    Time frame: day 0~7

  4. To evaluate if performing BDT with spirometry and with oscillometry is superior to either test alone

    The proportion of osci BDT ve+ who have spiro BDT positive. The proportion of osci BDT ve+ (excluding who have spiro BDT positive) who have spiro BPT positive. The number of asthma patients based on spiro BPT/BDT ve+, who have only osci BDT ve+ or spiro BDT ve+.

    Time frame: day 0~7

  5. To evaluate the diagnostic performance of portable oscillometry in asthma patients by lung functions impairment status

    PPV and NPV of BDT with portable oscillometry in asthma patients with FEV1%≥70% and FEV1%\<70%, respectively.

    Time frame: day 0~7

  6. To explore the diagnostic value of single parameter or combination of parameters in asthma patients

    Area Under the Receiver Operating Characteristic (ROC) Curve (AUC) for individual or combination of any parameter of portable oscillometry together with or without FeNO and/or EOS in asthma diagnosis.

    Time frame: day 0~7

  7. To explore the diagnostic performance of BDT with portable oscillometry based on thresholds from other studies

    The proportion of osci BDT ve+ according to the following thresholds reported in other studies. R5 decrease ≥32% or X5 increase ≥44% or AX decrease ≥65%. R5 decrease ≥29% or X5 increase ≥45%.

    Time frame: day 0~7

  8. To describe the change in pulmonary function parameters measured by portable oscillometry before and after bronchodilator use in diagnosed asthma patients

    Mean ± SD and percentile ranges (P₂.₅-P₉₇.₅) of the optimal oscillometry BDT variables (e.g., ΔRrs, ΔXrs, ΔAX) in diagnosed asthma patients.

    Time frame: day 0~7

Other outcomes

  1. To evaluate the safety of portable oscillometry

    Adverse events during oscillometry testing.

    Time frame: day 0~7

07

Study locations

17 of 24 sites recruiting
  • Research Site
    Beijing, 100000, China
    Recruiting
  • Research Site
    Cangzhou, 061000, China
    Recruiting
  • Research Site
    Changsha, 410008, China
    Not yet recruiting
  • Research Site
    Changsha, 430033, China
    Recruiting
  • Research Site
    Chengdu, 610041, China
    Recruiting
  • Research Site
    Chongqing, 400016, China
    Recruiting
  • Research Site
    Guangzhou, 510000, China
    Recruiting
  • Research Site
    Guangzhou, 510120, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510630, China
    Recruiting
  • Research Site
    Kunming, 650032, China
    Not yet recruiting
  • Research Site
    Quanzhou, 362000, China
    Recruiting
  • Research Site
    Shanghai, 200032, China
    Not yet recruiting
  • Research Site
    Shanghai, 200065, China
    Recruiting
  • Research Site
    Shanghai, 200080, China
    Recruiting
  • Research Site
    Shanghai, 200433, China
    Not yet recruiting
  • Research Site
    Suzhou, 215006, China
    Not yet recruiting
  • Research Site
    Taiyuan, 030001, China
    Recruiting
  • Research Site
    Tianjin, 300192, China
    Not yet recruiting
  • Research Site
    Ürümqi, 830054, China
    Recruiting
  • Research Site
    Wuhan, 430048, China
    Recruiting
  • Research Site
    Xi'an, 710004, China
    Recruiting
  • Research Site
    Yangzhou, 225001, China
    Recruiting
  • Research Site
    Zhengzhou, 450000, China
    Recruiting
  • Research Site
    Zhuhai, 519000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 50 industry-sponsored interventional studies with no phase under Asthma, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's planned 12 months is close to that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Apr 7, 2026
StartActual
Jun 10, 2026
Primary completionEst.
Jun 11, 2027
CompletionEst.
Jun 11, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed. 6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • Research Site · Cangzhou, ChinaNot yet recruiting→Recruiting
  • Research Site · Chengdu, ChinaNot yet recruiting→Recruiting
  • Research Site · Chongqing, ChinaNot yet recruiting→Recruiting
  • Research Site · Guangzhou, ChinaNot yet recruiting→Recruiting
  • Research Site · Xi'an, ChinaNot yet recruiting→Recruiting
  • Research Site · Yangzhou, ChinaNot yet recruiting→Recruiting
Show 1 removed
  • Research Site · Guangzhou, China
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    1 site removed. 6 sites changed recruiting status (6 now recruiting)
    Show 6 sites
    • Research Site · Cangzhou, ChinaNot yet recruiting→Recruiting
    • Research Site · Chengdu, ChinaNot yet recruiting→Recruiting
    • Research Site · Chongqing, ChinaNot yet recruiting→Recruiting
    • Research Site · Guangzhou, ChinaNot yet recruiting→Recruiting
    • Research Site · Xi'an, ChinaNot yet recruiting→Recruiting
    • Research Site · Yangzhou, ChinaNot yet recruiting→Recruiting
    Show 1 removed
    • Research Site · Guangzhou, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07516184
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Jun 10, 2026
Primary completion
Jun 11, 2027 (estimated)
Completion
Jun 11, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479
KeWu Huang, Doctor
principal investigator · Beijing Chao-Yang Hospital, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, China
Min Zhang, Doctor
principal investigator · No. 85/86, Wujin Road, Hongkou District, Shanghai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion